Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Journal of Managed Care & Specialty Pharmacy|March 1, 2021
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancerVivian Le, Lixian Zhong, NihaL Narsipur, et al.Journal of Managed Care & Specialty Pharmacy|November 24, 2021
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myelomaNihal Narsipur, Sabrina Bulla, Connie Yoo, et al.Advances in Therapy|June 18, 2026
Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema AttacksRaffi Tachdjian, Nihal Narsipur, Paranjoy Saharia, et al.Clinical and Experimental Medicine|January 14, 2026
Patient-reported disease burden and health care utilization of HAE-nl-C1INH: insights from a real-world surveyDouglas Jones, Nihal Narsipur, Sally W Wade, et al.Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids|October 12, 2018
Intake of stigmasterol and β-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style dietSimin Feng, Zhuqing Dai, Anna B Liu, et al.Advances in Therapy|May 2, 2026
Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment ComparisonJohn Anderson, Nihal Narsipur, Douglas Jones, et al.Diabetes, Obesity & Metabolism|March 31, 2023
Impact of pre-existing type 2 diabetes with and without cardiovascular disease on patients with COVID-19Chi Nguyen, Christopher L Crowe, Effie Kuti, et al.Advances in Therapy|May 20, 2026
Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary AngioedemaMarc A Riedl, Nihal Narsipur, Douglas Jones, et al.Pageof 1